Touchlight Expands mbDNA™ Portfolio with New Circular DNA Architectures for Advanced Therapies

LONDON, UK, November 05, 2025 / Biotech Newswire / -- Touchlight, a leader in cell-free DNA technology, today announced the expansion of its groundbreaking mbDNA™ platform with the introduction of three new circular DNA architectures: sscDNA, hsscDNA, and dscDNA. These innovative constructs join mbDNA, which debuted earlier this year, to form a comprehensive portfolio designed to overcome the limitations of traditional gene editing tools.
 
The mbDNA platform and new custom circle DNA architectures deliver enhanced stability, reduced immunogenicity, and compatibility with a broad range of gene insertion and expression technologies, setting a new standard for precision and performance in genetic engineering.
 
mbDNA (megabulb DNA) is a pioneering single-stranded DNA technology produced through Touchlight’s cell-free enzymatic platform, delivering high purity and minimal immunogenicity for safer outcomes plus enzymatic production for optimal reliability and scalability. It achieves high HDR efficiency with low toxicity, consistently reaching knock-in rates of 60–75% in primary T cells, while offering predictable performance with low donor-donor variability. Additionally, mbDNA supports expanded payload capacity of up to 20kb, enabling the delivery of large genetic cargos and unlocking new possibilities for advanced gene editing.
 
Applications include homology-directed repair (HDR), and episomal expression.
 
Introducing sscDNA, hsscDNA, and dscDNA


 
The flexible nature of Touchlight’s novel circular DNA molecules allows for bespoke designs to optimize gene therapy platforms that utilize DNA payloads for episomal expression or integration.  sscDNA is a fully single-stranded circular DNA molecule, whereas hsscDNA contains bespoke  double stranded region(s) of user-defined length.  dscDNA is a fully double stranded circular molecule. The sequence of all DNA constructs are completely user defined and ideal for transposases, recombinases, HITI, and episomal expression.
 
“mbDNA is a market leading technology providing the best-in-class HDR template available today,” said Karen Fallen, CEO at Touchlight. “With the addition of sscDNA, hsscDNA, and dscDNA, we’re empowering researchers and developers to unlock new possibilities in gene editing and therapeutic innovation.”
 
About Touchlight
Touchlight is an innovation-driven leading CDMO pioneering enzymatic GMP DNA production to enable the genetic medicine revolution. As pioneers with an FDA Drug Master File accepted in 2022, followed in 2025 with awarding of the world’s first cell-free DNA GMP license, Touchlight and its enzymatic DNA technology represent the cutting edge of viral vectors, mRNA, non-viral gene therapy, DNA vaccine and gene editing innovation. With multiple client products already in the clinic, Touchlight’s synthetic DNA manufacturing solutions offer a scalable, sustainable alternative to plasmid DNA (pDNA) supporting pre-clinical, clinical and commercial development. The Touchlight group and technology are built on the conviction that DNA is fundamental to the future of medicine. Traditional methods, based on bacterial fermentation, are slow, costly, and unable to meet the growing demands of genetic medicine due to limited scalability and speed. Founded in 2007, Touchlight’s team is inspired by breakthroughs in genetic medicine, recognising the urgent need for innovative DNA production techniques to support the future of genetic therapies. 
 
Contact
Touchlight 
Karen Fallen, Chief Executive Officer
Verna McErlane, Chief Commercial Officer
info@touchlight.com
+44 20 8481 9200
LinkedIn 
X
 
Keywords: Plasmids; DNA; Genetic Therapy; Technology; Nucleic Acids; Gene Editing; United Kingdom; Touchlight; mbDNA; cell-free DNA technology; circular DNA; sscDNA; hsscDNA; dscDNA; gene editing; gene therapy; genetic engineering; homology-directed repair; episomal expression; DNA architectures; DNA constructs; DNA payloads; single-stranded DNA; double stranded DNA; megabulb DNA; cell-free enzymatic platform; scalability; precision; performance; therapeutic innovation

Source: Biotech Newswire